InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,615.35
(
0.55%
)
US TECH 100
19,792.80
(
0.00%
)
Dow Jones
40,000.90
(
0.62%
)
Brent Oil
84.25
(
-0.41%
)
Bitcoin
62,885.48
(
3.46%
)
Post# of 30387
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

opportunityknocking

Send PM Follow Ignore
Followers 2
Posts 927
Boards Moderated 0
Alias Born 09/27/2005

opportunityknocking

Re: doggone01 post# 16430

Thursday, 10/02/2008 1:31:24 PM

Thursday, October 02, 2008 1:31:24 PM

Post# of 30387
The results for ovarian cancer using Serum-RECAF show a sensitivity of 90% with 95% specificity. The current marker of choice for ovarian cancer is CA-125 and it has a sensitivity of only 77% compared with the 90% found with Serum-RECAF.
It makes no sense that you insist recaf has no value. I beg to differ and clearly see it at face value for what is worth. Everyone knows you have one mission. Destroy Biocurex. Now debate that!
You are wrong and are only a lay person with a vendetta. This has been apparent for quite some time but I expect a great ISOBM in about one week, so enjoy your last jabs.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up